Medication info

Telostin Tablet 80/10 mg

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Telmisartan›80mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Daehwa Pharmaceutical Co., Ltd.
Appearance
Bright blue oval film-coated tablet
Packaging
30 tablets/box [(10 tablets/PTP*3)]
Approval status
Approval withdrawn

MFDS item code 202001839 · Approved 2020.03.17

This product's status changed to Approval withdrawn on 2024.12.04. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension and dyslipidemia; prevention of cardiovascular disease; inhibition of atherosclerosis progression
Who takes it
Adults
Adult dose
In a drug interaction study of the active ingredients of this medicine, telmisartan 80mg and rosuvastatin 20mg, in the presence of rosuvastatin, the Cmax of telmisartan was approximately 0.87-fold and its AUC was approximately 1.00-fold; in the presence of telmisartan, the Cmax of rosuvastatin increased approximately 1.71-fold and its AUC increased approximately 1.16-fold. Therefore, when administering this medicine, assess the potential risk due to the increase in rosuvastatin Cmax and monitor patients closely. This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each of its components, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This medicine produces an additional blood pressure-lowering effect when administered concomitantly with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after treatment is started. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reducing effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased up to a maximum of 20 milligrams daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a fixed-dose combination containing the same amount of each active ingredient) for convenience.

Ingredients

Manufacturer
Daehwa Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia; prevention of cardiovascular disease; inhibition of atherosclerosis progression

  • Essential hypertension
  • coronary artery disease
  • peripheral artery disease
  • stroke
  • transient ischemic attack
  • clinical evidence of end-organ damage
  • high-risk diabetes
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
View approved original text

This medication is used only for patients who need to take both telmisartan and rosuvastatin simultaneously. Telmisartan treats essential hypertension and reduces the risk of cardiovascular diseases, particularly in high-risk groups, reducing the risk of myocardial infarction, stroke, and mortality from cardiovascular diseases. Meanwhile, rosuvastatin helps control blood lipid abnormalities, such as hypercholesterolemia and dyslipidemia, slowing the progression of atherosclerosis and reducing various risks associated with cardiovascular diseases. By working together, these two components effectively manage hypertension and hyperlipidemia, thereby improving cardiovascular health.

How to take

Adult dose

In a drug interaction study of the active ingredients of this medicine, telmisartan 80mg and rosuvastatin 20mg, in the presence of rosuvastatin, the Cmax of telmisartan was approximately 0.87-fold and its AUC was approximately 1.00-fold; in the presence of telmisartan, the Cmax of rosuvastatin increased approximately 1.71-fold and its AUC increased approximately 1.16-fold. Therefore, when administering this medicine, assess the potential risk due to the increase in rosuvastatin Cmax and monitor patients closely. This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each of its components, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This medicine produces an additional blood pressure-lowering effect when administered concomitantly with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after treatment is started. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reducing effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased up to a maximum of 20 milligrams daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a fixed-dose combination containing the same amount of each active ingredient) for convenience.

Precautions

This medication can cause severe harm to the fetus if used during pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. People allergic to this medication or its components should not use it. Women who are pregnant, may become pregnant, or are breastfeeding should not take this medication, and fertile women who do not use adequate contraceptive measures should be cautious. Patients with severely impaired liver function or biliary obstruction, as well as those with active liver disease, should not take this medication. Patients with muscle disorders or a history of angioedema, and those with severe renal impairment, should also avoid using this medication. In particular, patients taking cyclosporine or those with diabetes and moderate to severe renal impairment are contraindicated from coadministration. High-dose administration of this medication is prohibited in patients at high risk for myopathy or rhabdomyolysis, and those patients should consult their doctor before taking it. Patients with genetically determined lactose intolerance should not take this medication due to its lactose content. Elderly patients, those with hyperkalemia, and patients with mildly impaired liver function should use this medication cautiously and undergo regular liver function tests and blood tests. Patients with cardiovascular or gastrointestinal diseases, and renal vascular hypertension should also be cautious when taking this medication. If symptoms like muscle pain, muscle weakness, or muscle cramps occur while taking this medication, consult a physician immediately, and necessary muscle enzyme tests should be conducted to check for abnormalities. This medication can interact with other antihypertensive or lipid-lowering medications, so inform your doctor of any other medications being taken. It is important to check muscle enzymes and liver function through blood tests before starting treatment and regularly during treatment. Women who are pregnant or breastfeeding should avoid taking this medication, and those planning to become pregnant should use adequate contraceptive measures. The safety and efficacy of this medication in children have not been established, so it is not recommended for pediatric use. In case of overdose, symptoms such as hypotension, dizziness, and acute renal failure may occur, requiring immediate visit to a medical institution, as there is no specific antidote and symptomatic treatment is necessary. Be cautious when driving or operating machinery, as dizziness or drowsiness may occur during the course of medication. Finally, store this medication out of reach of children and do not transfer it to other containers for safety.

Side effects

Headache, positional dizziness, sleep paralysis, increased blood pressure, decreased blood pressure, hypotension, elevated ALT, dysuria, rhinitis, pharyngeal discomfort, lung disease, unspecified gastrointestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory tract infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, orthostatic hypotension, shortness of breath, abdominal pain, diarrhea, dyspepsia, abdominal fullness, vomiting, abdominal discomfort, dry mouth, liver function abnormalities, liver disorder, increased sweating, itching, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, hives, myalgia, back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute kidney failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, increased liver enzymes, elevated serum CK, decreased hemoglobin, hypoglycemia, angioedema, hypersensitivity reaction including angioedema, diabetes, headache, dizziness, constipation, nausea, pancreatitis, pruritus, rash, hives, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, shortness of breath, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia and systemic symptom drug reaction syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia, facial spasms, sensory abnormalities, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, weakness, edema, decreased libido, facial edema, alopecia, conjunctivitis, tinnitus, petechiae, palpitations, fatigue, nausea, lack of effect, cough, palpitations, constipation, increased AST, numbness, sensory abnormalities, chest discomfort, loss of appetite, abdominal bloating, syncope, generalized pain, muscle cramps, gout

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. Also, avoid storing it in excessively hot or cold locations, and it is best to keep it at room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Bright blue oval film-coated tablet

Package unit

30 tablets/box [(10 tablets/PTP*3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.